allergy treatments

Net earnings at the pharmaceutical company rose 6.9% to $5.14 billion, or $1.96 a share. Net earnings at the pharmaceutical company rose 6.9% to $5.14 billion, or $1.96 a share. FOLLOW US ON GOOGLE NEWS Read original article here Denial of responsibility! Techno Blender is an automatic aggregator of the all world’s media. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to their authors. If you are the owner of the content and do…

The world’s only approved peanut allergy drug has so far proved a flop. Nestlé SA said Tuesday it would explore strategic options for the treatment, effectively putting the drug up for sale, following lower-than-expected demand from doctors and patients. The move comes just two years after the packaged-food giant agreed to buy the developer of the drug, called Palforzia, in a $2.6 billion deal. “We did have high hopes for this business,” Nestlé Chief Executive…